|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Wolpin BM and Mayer RJ: Systemic treatment
of colorectal cancer. Gastroenterology. 134:1296–1310. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Kratzer TB, Wagle NS, Sung H
and Jemal A: Cancer statistics, 2026. CA Cancer J Clin.
76:e700432026.PubMed/NCBI
|
|
4
|
Wang Y, Qiu X, Li Q, Qin J, Ye L, Zhang X,
Huang X, Wen X, Wang Z, He W, et al: Single-cell and
spatial-resolved profiling reveals cancer-associated fibroblast
heterogeneity in colorectal cancer metabolic subtypes. J Transl
Med. 23:1752025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Valdeolivas A, Amberg B, Giroud N,
Richardson M, Gálvez EJC, Badillo S, Julien-Laferrière A, Túrós D,
Voith von Voithenberg L, Wells I, et al: Profiling the
heterogeneity of colorectal cancer consensus molecular subtypes
using spatial transcriptomics. NPJ Precis Oncol. 8:102024.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ogden S, Metic N, Leylek O, Smith EA,
Berner AM, Baker AM, Uddin I, Buzzetti M, Gerlinger M; Cancer
Tissue Bank, ; et al: Phenotypic heterogeneity and plasticity in
colorectal cancer metastasis. Cell Genom. 5:1008812025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Biswas SK: Metabolic reprogramming of
immune cells in cancer progression. Immunity. 43:435–449. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koundouros N and Poulogiannis P:
Reprogramming of fatty acid metabolism in cancer. Br J Cancer.
122:4–22. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hwang HS, Kim D and Choi J: Distinct
mutational profile and immune microenvironment in
microsatellite-unstable and POLE-mutated tumors. J Immunother
Cancer. 9:e0027972021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin B, Du L, Li H, Zhu X, Cui L and Li X:
Tumor-infiltrating lymphocytes: Warriors fight against tumors
powerfully. Biomed Pharmacother. 132:1108732020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu H, Wang S, Wang J, Guo X, Song Y, Fu
K, Gao Z, Liu D, He W and Yang LL: Energy metabolism in health and
diseases. Signal Transduct Target Ther. 10:692025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brudno JN, Maus MV and Hinrichs CS: CAR T
cells and T-cell therapies for cancer: A translational science
review. JAMA. 332:1924–1935. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kantarjian H, Stein A, Gökbuget N,
Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan
R, et al: Blinatumomab versus chemotherapy for advanced acute
lymphoblastic leukemia. N Engl J Med. 376:836–847. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giles JR, Globig AM, Kaech SM and Wherry
EJ: CD8+ T cells in the cancer-immunity cycle. Immunity.
56:2231–2253. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lerner EC, Woroniecka KI, D'Anniballe VM,
Wilkinson DS, Mohan AA, Lorrey SJ, Waibl-Polania J, Wachsmuth LP,
Miggelbrink AM, Jackson JD, et al: CD8+ T cells maintain
killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL
axis. Nat Cancer. 4:1258–1272. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
MacNabb BW, Chen X, Tumuluru S, Godfrey J,
Kasal DN, Yu J, Jongsma MLM, Spaapen RM, Kline DE and Kline J:
Dendritic cells can prime anti-tumor CD8+ T cell
responses through major histocompatibility complex cross-dressing.
Immunity. 55:2206–2208. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Frisch AT, Wang Y, Xie B, Yang A, Ford BR,
Joshi S, Kedziora KM, Peralta R, Wilfahrt D, Mullett SJ, et al:
Redirecting glucose flux during in vitro expansion generates
epigenetically and metabolically superior T cells for cancer
immunotherapy. Cell Metab. 37:870–885.e8. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Markowitz GJ, Ban Y, Tavarez DA, Yoffe L,
Podaza E, He Y, Martin MT, Crowley MJP, Sandoval TA, Gao D, et al:
Deficiency of metabolic regulator PKM2 activates the pentose
phosphate pathway and generates TCF1+ progenitor
CD8+ T cells to improve immunotherapy. Nat Immunol.
25:1884–1899. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mortazavi Farsani SS, Soni J, Jin L, Yadav
AK, Bansal S, Mi T, Hilakivi-Clarke L, Clarke R, Youngblood B,
Cheema A and Verma V: Pyruvate kinase M2 activation reprograms
mitochondria in CD8 T cells, enhancing effector functions and
efficacy of anti-PD1 therapy. Cell Metab. 37:1294–1310.e7. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qiu Y, Su Y, Xie E, Cheng H, Du J, Xu Y,
Pan X, Wang Z, Chen DG, Zhu H, et al: Mannose metabolism reshapes T
cell differentiation to enhance anti-tumor immunity. Cancer Cell.
43:103–121.e8. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Patel CH and Powell JD: Targeting T cell
metabolism to regulate T cell activation, differentiation and
function in disease. Curr Opin Immunol. 46:82–88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Notarangelo G, Spinelli JB, Perez EM,
Baker GJ, Kurmi K, Elia I, Stopka SA, Baquer G, Lin JR, Golby AJ,
et al: Oncometabolite d-2HG alters T cell metabolism to impair
CD8+ T cell function. Science. 377:1519–1529. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Willson J: Tumour-derived D-2HG blocks T
cell cytotoxicity. Nat Rev Cancer. 22:6572022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Trefny MP, Kroemer G, Zitvogel L and
Kobold S: Metabolites as agents and targets for cancer
immunotherapy. Nat Rev Drug Discov. 24:764–784. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chu X, Li X, Zhang Y, Dang G, Miao Y, Xu
W, Wang J, Zhang Z and Cheng S: Integrative single-cell analysis of
human colorectal cancer reveals patient stratification with
distinct immune evasion mechanisms. Nat Cancer. 5:1409–1426. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sterner RC and Sterner RM: CAR-T cell
therapy: Current limitations and potential strategies. Blood Cancer
J. 11:692021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liberti MV and Locasale JW: The Warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leone RD and Powell JD: Metabolism of
immune cells in cancer. Nat Rev Cancer. 9:516–531. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chang CH, Qiu J, O'Sullivan D, Buck MD,
Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ,
et al: Metabolic competition in the tumor microenvironment is a
driver of cancer progression. Cell. 162:1229–1241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brand A, Singer K, Koehl GE, Kolitzus M,
Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, et
al: LDHA-associated lactic acid production blunts tumor
immunosurveillance by T and NK cells. Cell Metab. 24:657–671. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu Y, Zhang Q, Xing B, Luo N, Gao R, Yu
K, Hu X, Bu Z, Peng J, Ren X and Zhang Z: Immune phenotypic linkage
between colorectal cancer and liver metastasis. Cancer Cell.
40:424–437.e5. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Damiani C, Colombo R, Gaglio D,
Mastroianni F, Pescini D, Westerhoff HV, Mauri G, Vanoni M and
Alberghina L: A metabolic core model elucidates how enhanced
utilization of glucose and glutamine, with enhanced
glutamine-dependent lactate production, promotes cancer cell
growth: The WarburQ effect. PLoS Comput Biol. 13:e10057582017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoo HC, Yu YC, Sung Y and Han JM:
Glutamine reliance in cell metabolism. Exp Mol Med. 52:1496–1516.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen TH, Wang HC, Chang CJ and Lee SY:
Mitochondrial glutathione in cellular redox homeostasis and disease
manifestation. Int J Mol Sci. 25:13142024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bai C, Hua J, Meng D, Xu Y, Zhong B, Liu
M, Wang Z, Zhou W, Liu L, Wang H, et al: Glutaminase-1 mediated
glutaminolysis to glutathione synthesis maintains redox homeostasis
and modulates ferroptosis sensitivity in cancer cells. Cell Prolif.
11:e700362025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ko YH, Lin Z, Flomenberg N, Pestell RG,
Howell A, Sotgia F, Lisanti MP and Martinez-Outschoorn UE:
Glutamine fuels a vicious cycle of autophagy in the tumor stroma
and oxidative mitochondrial metabolism in epithelial cancer cells:
Implications for preventing chemotherapy resistance. Cancer Biol
Ther. 12:1085–1097. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Edwards DN, Ngwa VM, Raybuck AL, Wang S,
Hwang Y, Kim LC, Cho SH, Paik Y, Wang Q, Zhang S, et al: Selective
glutamine metabolism inhibition in tumor cells improves antitumor T
lymphocyte activity in triple-negative breast cancer. J Clin
Invest. 131:e1401002021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Matias MI, Yong CS, Foroushani A,
Goldsmith C, Mongellaz C, Sezgin E, Levental KR, Talebi A, Perrault
J, Rivière A, et al: Regulatory T cell differentiation is
controlled by αKG-induced alterations in mitochondrial metabolism
and lipid homeostasis. Cell Rep. 37:1099112021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Johnson MO, Wolf MM, Madden MZ, Andrejeva
G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton
RJ, et al: Distinct regulation of Th17 and Th1 cell differentiation
by glutaminase-dependent metabolism. Cell. 175:1780–1795.e19. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cao J, Qin S, Li B, Zhang Z, Miao P, Yan
H, Duan J, He B, He K, Peng P, et al: Extracellular vesicle-induced
lipid dysregulation drives liver premetastatic niche formation in
colorectal cancer. Gut. 74:2012–2023. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ma X, Xiao L, Liu L, Ye L, Su P, Bi E,
Wang Q, Yang M, Qian J and Yi Q: CD36-mediated ferroptosis dampens
intratumoral CD8+ T cell effector function and impairs
their antitumor ability. Cell Metab. 33:1001–1012.e5. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xing J, Man C, Liu Y, Zhang Z and Peng H:
Factors impacting the benefits and pathogenicity of Th17 cells in
the tumor microenvironment. Front Immunol. 14:12242692023.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cerboni S, Gehrmann U, Preite S and Mitra
S: Cytokine-regulated Th17 plasticity in human health and diseases.
Immunology. 163:3–18. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pacella I, Procaccini C, Focaccetti C,
Miacci S, Timperi E, Faicchia D, Severa M, Rizzo F, Coccia EM,
Bonacina F, et al: Fatty acid metabolism complements glycolysis in
the selective regulatory T cell expansion during tumor growth. Proc
Natl Acad Sci USA. 115:E6546–E6555. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cascone T, McKenzie JA, Mbofung RM, Punt
S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, et al:
Increased tumor glycolysis characterizes immune resistance to
adoptive T cell therapy. Cell Metab. 27:977–987.e4. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qiao Q, Hu S and Wang X: The regulatory
roles and clinical significance of glycolysis in tumor. Cancer
Commun (Lond). 44:761–786. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shen YM, Arbman G, Olsson B and Sun XF:
Overexpression of GLUT1 in colorectal cancer is independently
associated with poor prognosis. Int J Biol Markers. 26:166–172.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yuan R, Ke J, Sun L, He Z, Zou Y, He X,
Chen Y, Wu X, Cai Z, Wang L, et al: HES1 promotes metastasis and
predicts poor survival in patients with colorectal cancer. Clin Exp
Metastasis. 32:169–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Weng MT, Tsao PN, Lin HL, Tung CC, Change
MC, Chang YT, Wong JM and Wei SC: Hes1 increases the invasion
ability of colorectal cancer cells via the STAT3-MMP14 pathway.
PLoS One. 10:e01443222015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang J, Zhu M, Zhu J, Li J, Zhu X, Wang K,
Shen K, Yang K, Ni X, Liu X, et al: HES1 promotes aerobic
glycolysis and cancer progression of colorectal cancer via
IGF2BP2-mediated GLUT1 m6A modification. Cell Death Discov.
9:4112023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhou D, Yao Y, Zong L, Zhou G, Feng M,
Chen J, Liu G, Chen G, Sun K, Yao H, et al: TBK1 facilitates
GLUT1-dependent glucose consumption by suppressing mTORC1 signaling
in colorectal cancer progression. Int J Biol Sci. 18:3374–3389.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hayashi M, Nakamura K, Harada S, Tanaka M,
Kobayashi A, Saito H, Tsuji T, Yamamoto D, Moriyama H, Kinoshita J
and Inaki N: GLUT1 inhibition by BAY-876 induces metabolic changes
and cell death in human colorectal cancer cells. BMC Cancer.
25:7162025. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sun X, Peng Y, Zhao J, Xie Z, Lei X and
Tang G: Discovery and development of tumor glycolysis rate-limiting
enzyme inhibitors. Bioorg Chem. 112:1048912021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sawant Dessai A, Kalhotra P, Novickis AT
and Dasgupta S: Regulation of tumor metabolism by post
translational modifications on metabolic enzymes. Cancer Gene Ther.
30:548–558. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhong J, Lu S, Jia X, Li Q, Liu L, Xie P,
Wang G, Lu M, Gao W, Zhao T, et al: Role of endoplasmic reticulum
stress in apoptosis induced by HK2 inhibitor and its potential as a
new drug combination strategy. Cell Stress Chaperones. 27:273–283.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ma L, Zhang X, Liu Y, Jin H, Li D, Zhang
H, Feng L, Zuo J, Wang Y, Liu J and Han J: The ratio of PKM1/PKM2
is the key factor affecting the glucose metabolism and biological
function of colorectal cancer cells. Transl Cancer Res.
13:3522–3535. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhao J, Li J, Hassan W, Xu D, Wang X and
Huang Z: Sam68 promotes aerobic glycolysis in colorectal cancer by
regulating PKM2 alternative splicing. Ann Transl Med. 8:4592020.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chen D, Liu P, Lu X, Li J, Qi D, Zang L,
Lin J, Liu Y, Zhai S, Fu D, et al: Pan-cancer analysis implicates
novel insights of lactate metabolism into immunotherapy response
prediction and survival prognostication. J Exp Clin Cancer Res.
43:1252024. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhou M, He J, Li Y, Jiang L, Ran J, Wang
C, Ju C, Du D, Xu X, Wang X, et al: N6-methyladenosine
modification of REG1α facilitates colorectal cancer progression via
β-catenin/MYC/LDHA axis mediated glycolytic reprogramming. Cell
Death Dis. 14:5572023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang R, Xu F, Yang Z, Cao J, Hu L and She
Y: The mechanism of PFK-1 in the occurrence and development of
bladder cancer by regulating ZEB1 lactylation. BMC Urol. 24:592024.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yan S, Li Q, Li S, Ai Z and Yuan D: The
role of PFKFB3 in maintaining colorectal cancer cell proliferation
and stemness. Mol Biol Rep. 49:9877–9891. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lu S, Zhao R, Han Y, Shao S, Ji Y, Zhang
J, Pan H, Sun J and Feng Y: Identification of PFKFB3 as a key
factor in the development of colorectal cancer and immunotherapy
resistance. Clin Exp Med. 24:2192024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Song M, Sandoval TA, Chae CS, Chopra S,
Tan C, Rutkowski MR, Raundhal M, Chaurio RA, Payne KK, Konrad C, et
al: IRE1α-XBP1 controls T cell function in ovarian cancer by
regulating mitochondrial activity. Nature. 562:423–428. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tay C, Tanaka A and Sakaguchi S:
Tumor-infiltrating regulatory T cells as targets of cancer
immunotherapy. Cancer Cell. 41:450–465. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Jiang B, Zhang J, Zhao G, Liu M, Hu J, Lin
F, Wang J, Zhao W, Ma H, Zhang C, et al: Filamentous GLS1 promotes
ROS-induced apoptosis upon glutamine deprivation via insufficient
asparagine synthesis. Mol Cell. 82:1821–1835.e6. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Villar VH, Allega MF, Deshmukh R,
Ackermann T, Nakasone MA, Vande Voorde J, Drake TM, Oetjen J, Bloom
A, Nixon C, et al: Hepatic glutamine synthetase controls
N5-methylglutamine in homeostasis and cancer. Nat Chem
Biol. 19:292–300. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Shang M, Cappellesso F, Amorim R, Serneels
J, Virga F, Eelen G, Carobbio S, Rincon MY, Maechler P, De Bock K,
et al: Macrophage-derived glutamine boosts satellite cells and
muscle regeneration. Nature. 587:626–631. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Chen Y, Tan L, Gao J, Lin C, Wu F, Li Y
and Zhang J: Targeting glutaminase 1 (GLS1) by small molecules for
anticancer therapeutics. Eur J Med Chem. 252:1153062023. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Liu HY, Zhang HS, Liu MY, Li HM, Wang XY
and Wang M: GLS1 depletion inhibited colorectal cancer
proliferation and migration via redox/Nrf2/autophagy-dependent
pathway. Arch Biochem Biophys. 708:1089642021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Miyamoto R, Takigawa H, Yuge R, Shimizu D,
Ariyoshi M, Otani R, Tsuboi A, Tanaka H, Yamashita K, Hiyama Y, et
al: Analysis of anti-tumor effect and mechanism of GLS1 inhibitor
CB-839 in colorectal cancer using a stroma-abundant tumor model.
Exp Mol Pathol. 137:1048962024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lukey MJ, Cluntun AA, Katt WP, Lin MJ,
Druso JE, Ramachandran S, Erickson JW, Le HH, Wang ZE, Blank B, et
al: Liver-type glutaminase GLS2 is a druggable metabolic node in
luminal-subtype breast cancer. Cell Rep. 29:76–88.e7. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kim GW, Lee DH, Jeon YH, Yoo J, Kim SY,
Lee SW, Cho HY and Kwon SH: Glutamine synthetase as a therapeutic
target for cancer treatment. Int J Mol Sci. 22:17012021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Palmieri EM, Menga A, Martín-Pérez R,
Quinto A, Riera-Domingo C, De Tullio G, Hooper DC, Lamers WH,
Ghesquière B, McVicar DW, et al: Pharmacologic or genetic targeting
of glutamine synthetase skews macrophages toward an M1-like
phenotype and inhibits tumor metastasis. Cell Rep. 20:1654–1666.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Liu G, Zhu J, Yu M, Cai C, Zhou Y, Yu M,
Fu Z, Gong Y, Yang B, Li Y, et al: Glutamate dehydrogenase is a
novel prognostic marker and predicts metastases in colorectal
cancer patients. J Transl Med. 13:1442015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ayinde O, Wang Z and Griffin M: Tissue
transglutaminase induces epithelial-mesenchymal-transition and the
acquisition of stem cell like characteristics in colorectal cancer
cells. Oncotarget. 8:20025–20041. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ayinde O, Wang Z, Pinton G, Moro L and
Griffin M: Transglutaminase 2 maintains a colorectal cancer stem
phenotype by regulating epithelial-mesenchymal transition.
Oncotarget. 10:4556–4569. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Scalise M, Pochini L, Console L, Losso MA
and Indiveri C: The human SLC1A5 (ASCT2) amino acid transporter:
From function to structure and role in cell biology. Front Cell Dev
Biol. 6:962018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Bröer A, Rahimi F and Bröer S: Deletion of
amino acid transporter ASCT2 (SLC1A5) reveals an essential role for
transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain
glutaminolysis in cancer cells. J Biol Chem. 291:13194–13205. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Schulte ML, Fu A, Zhao P, Li J, Geng L,
Smith ST, Kondo J, Coffey RJ, Johnson MO, Rathmell JC, et al:
Pharmacological blockade of ASCT2-dependent glutamine transport
leads to antitumor efficacy in preclinical models. Nat Med.
24:194–202. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Dejure FR, Butzer J, Lindemann RK and
Mardin BR: Exploiting the metabolic dependencies of the broad amino
acid transporter SLC6A14. Oncotarget. 11:4490–4503. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Sniegowski T, Korac K, Bhutia YD and
Ganapathy V: SLC6A14 and SLC38A5 drive the glutaminolysis and
serine-glycine-one-carbon pathways in cancer. Pharmaceuticals
(Basel). 14:2162021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Nałęcz KA: Amino acid transporter SLC6A14
(ATB0,+)-a target in combined anti-cancer therapy. Front
Cell Dev Biol. 8:5944642020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Lu Y, Jiang Z, Wang K, Yu S, Hao C, Ma Z,
Fu X, Qin MQ, Xu Z and Fan L: Blockade of the amino acid
transporter SLC6A14 suppresses tumor growth in colorectal cancer.
BMC Cancer. 22:8332022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Peng W and Zeng Z: Epigenetic activation
of PTCD3 Promotes CRC glutamine metabolism and metastasis via
IGF2BP2-mediated SLC38A2 m6A modification. FASEB J. 39:e705582025.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Najumudeen AK, Ceteci F, Fey SK, Hamm G,
Steven RT, Hall H, Nikula CJ, Dexter A, Murta T, Race AM, et al:
The amino acid transporter SLC7A5 is required for efficient growth
of KRAS-mutant colorectal cancer. Nat Genet. 53:16–26. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Shen W, Xu T, Chen D and Tan X: Targeting
SREBP1 chemosensitizes colorectal cancer cells to gemcitabine by
caspase-7 upregulation. Bioengineered. 10:459–468. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wen YA, Xiong X, Zaytseva YY, Napier DL,
Vallee E, Li AT, Wang C, Weiss HL, Evers BM and Gao T:
Downregulation of SREBP inhibits tumor growth and initiation by
altering cellular metabolism in colon cancer. Cell Death Dis.
9:2652018. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Qiu Z, Deng W, Hong Y, Zhao L, Li M, Guan
Y, Su Y, Chen C, Shi Q, Yu J and Wang W: Biological behavior and
lipid metabolism of colon cancer cells are regulated by a
combination of sterol regulatory element-binding protein 1 and ATP
citrate lyase. Onco Targets Ther. 14:1531–1542. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wen J, Min X, Shen M, Hua Q, Han Y, Zhao
L, Liu L, Huang G, Liu J and Zhao X: ACLY facilitates colon cancer
cell metastasis by CTNNB1. J Exp Clin Cancer Res. 38:4012019.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Shan J, Li X, Sun R, Yao Y and Sun Y,
Kuang Q, Dai X and Sun Y: Palmitoyltransferase ZDHHC6 promotes
colon tumorigenesis by targeting PPARγ-driven lipid biosynthesis
via regulating lipidome metabolic reprogramming. J Exp Clin Cancer
Res. 43:2272024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Xiong X, Wen YA, Fairchild R, Zaytseva YY,
Weiss HL, Evers BM and Gao T: Upregulation of CPT1A is essential
for the tumor-promoting effect of adipocytes in colon cancer. Cell
Death Dis. 11:7362020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wang YN, Zeng ZL, Lu J, Wang Y, Liu ZX, He
MM, Zhao Q, Wang ZX, Li T, Lu YX, et al: CPT1A-mediated fatty acid
oxidation promotes colorectal cancer cell metastasis by inhibiting
anoikis. Oncogene. 37:6025–6040. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Paumen MB, Ishida Y, Han H, Muramatsu M,
Eguchi Y, Tsujimoto Y and Honjo T: Direct interaction of the
mitochondrial membrane protein carnitine palmitoyltransferase I
with Bcl-2. Biochem Biophys Res Commun. 231:523–525. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Yin H, Li W, Mo L, Deng S, Lin W, Ma C,
Luo Z, Luo C and Hong H: Adipose triglyceride lipase promotes the
proliferation of colorectal cancer cells via enhancing the
lipolytic pathway. J Cell Mol Med. 25:3963–3975. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Wang Y, Xu C, Yang X, Liu X, Guo Z, Lin X,
Li L and Huang Z: Glycerol-3-phosphate acyltransferase 3-mediated
lipid droplets accumulation confers chemoresistance of colorectal
cancer. MedComm (2020). 5:e4862024. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Lian W, Wang Z, Ma Y, Tong Y, Zhang X, Jin
H, Zhao S, Yu R, Ju S, Zhang X, et al: FABP6 expression correlates
with immune infiltration and immunogenicity in colorectal cancer
cells. J Immunol Res. 2022:31297652022. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Hua W, Ten Dijke P, Kostidis S, Giera M
and Hornsveld M: TGFβ-induced metabolic reprogramming during
epithelial-to-mesenchymal transition in cancer. Cell Mol Life Sci.
77:2103–2123. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Tian W, Zhang W, Zhang Y, Zhu T, Hua Y, Li
H, Zhang Q and Xia M: FABP4 promotes invasion and metastasis of
colon cancer by regulating fatty acid transport. Cancer Cell Int.
20:5122020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Kawaguchi K, Senga S, Kubota C, Kawamura
Y, Ke Y and Fujii H: High expression of fatty acid-binding protein
5 promotes cell growth and metastatic potential of colorectal
cancer cells. FEBS Open Bio. 6:190–199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Lu T, Sun L, Wang Z, Zhang Y, He Z and Xu
C: Fatty acid synthase enhances colorectal cancer cell
proliferation and metastasis via regulating AMPK/mTOR pathway. Onco
Targets Ther. 12:3339–3347. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Zaytseva YY, Rychahou PG, Le AT, Scott TL,
Flight RM, Kim JT, Harris J, Liu J, Wang C, Morris AJ, et al:
Preclinical evaluation of novel fatty acid synthase inhibitors in
primary colorectal cancer cells and a patient-derived xenograft
model of colorectal cancer. Oncotarget. 9:24787–24800. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Liu X, Lu J, Ni X, He Y, Wang J, Deng Z,
Zhang G, Shi T and Chen W: FASN promotes lipid metabolism and
progression in colorectal cancer via the SP1/PLA2G4B axis. Cell
Death Discov. 11:1222025. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Soriano-Baguet L and Brenner D: Metabolism
and epigenetics at the heart of T cell function. Trends Immun.
44:231–244. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
McGuire PJ: Chemical individuality in T
cells: A Garrodian view of immunometabolism. Immunol Rev.
295:82–100. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Chapman NM, Boothby MR and Chi H:
Metabolic coordination of T cell quiescence and activation. Nat Rev
Immunol. 20:55–70. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Esensten JH, Helou YA, Chopra G, Weiss A
and Bluestone JA: CD28 costimulation: from mechanism to therapy.
Immunity. 44:973–988. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Frauwirth KA, Riley JL, Harris MH, Parry
RV, Rathmell JC, Plas DR, Elstrom RL, June CH and Thompson CB: The
CD28 signaling pathway regulates glucose metabolism. Immunity.
16:769–777. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Mendoza A, Fang V, Chen C, Serasinghe M,
Verma A, Muller J, Chaluvadi VS, Dustin ML, Hla T, Elemento O, et
al: Lymphatic endothelial S1P promotes mitochondrial function and
survival in naive T cells. Nature. 546:158–161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
MacIver NJ, Michalek RD and Rathmell JC:
Metabolic regulation of T lymphocytes. Annu Rev Immunol.
31:259–283. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
O'Neill LA, Kishton RJ and Rathmell J: A
guide to immunometabolism for immunologists. Nat Rev Immunol.
16:553–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Bantug GR, Fischer M, Grählert J, Balmer
ML, Unterstab G, Develioglu L, Steiner R, Zhang L, Costa ASH,
Gubser PM, et al: Mitochondria-endoplasmic reticulum contact sites
function as immunometabolic hubs that orchestrate the rapid recall
response of memory CD8+ T cells. Immunity.
48:542–555.e6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Blank CU, Haining WN, Held W, Hogan PG,
Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, et al:
Defining ‘T cell exhaustion’. Nat Rev Immunol. 19:665–674. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Bengsch B, Johnson AL, Kurachi M, Odorizzi
PM, Pauken KE, Attanasio J, Stelekati E, McLane LM, Paley MA,
Delgoffe GM and Wherry EJ: Bioenergetic insufficiencies due to
metabolic alterations regulated by the inhibitory receptor PD-1 are
an early driver of CD8(+) T cell exhaustion. Immunity. 45:358–373.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Saxton RA and Sabatini DM: mTOR signaling
in growth, metabolism, and disease. Cell. 169:361–371. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Dibble CC and Manning BD: Signal
integration by mTORC1 coordinates nutrient input with biosynthetic
output. Nat Cell Biol. 15:555–564. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Finlay DK, Rosenzweig E, Sinclair LV,
Feijoo-Carnero C, Hukelmann JL, Rolf J, Panteleyev AA, Okkenhaug K
and Cantrell DA: PDK1 regulation of mTOR and hypoxia-inducible
factor 1 integrate metabolism and migration of CD8+ T cells. J Exp
Med. 209:2441–2453. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Rao RR, Li Q, Odunsi K and Shrikant PA:
The mTOR kinase determines effector versus memory CD8+ T cell fate
by regulating the expression of transcription factors T-bet and
Eomesodermin. Immunity. 32:67–78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Sukumar M, Liu J, Ji Y, Subramanian M,
Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly
ED, et al: Inhibiting glycolytic metabolism enhances CD8+ T cell
memory and antitumor function. J Clin Invest. 123:4479–4488. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Zhang M, Hu Y, Qian P and Huang H:
Inhibition of CD38 enzymatic activity enhances CAR-T cell
immune-therapeutic efficacy by repressing glycolytic metabolism.
Cell Rep Med. 5:1014002024. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zhu M, Han Y, Gu T, Wang R, Si X, Kong D,
Zhao P, Wang X, Li J, Zhai X, et al: Class I HDAC inhibitors
enhance antitumor efficacy and persistence of CAR-T cells by
activation of the Wnt pathway. Cell Rep. 43:1140652024. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang
G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis GC, et
al: Enhancing CD8+ T cell fatty acid catabolism within a
metabolically challenging tumor microenvironment increases the
efficacy of melanoma immunotherapy. Cancer Cell. 32:377–391.e9.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Chamoto K, Chowdhury PS, Kumar A, Sonomura
K, Matsuda F, Fagarasan S and Honjo T: Mitochondrial activation
chemicals synergize with surface receptor PD-1 blockade for T
cell-dependent antitumor activity. Proc Natl Acad Sci USA.
114:E761–E770. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Silverstein RL and Febbraio M: CD36, a
scavenger receptor involved in immunity, metabolism, angiogenesis,
and behavior. Sci Signal. 72:re32009.PubMed/NCBI
|
|
124
|
Xu S, Chaudhary O, Rodríguez-Morales P,
Sun X, Chen D, Zappasodi R, Xu Z, Pinto AFM, Williams A, Schulze I,
et al: Uptake of oxidized lipids by the scavenger receptor CD36
promotes lipid peroxidation and dysfunction in CD8+ T
cells in tumors. Immunity. 54:1561–1577.e7. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Hueto JA, Bescós C, Di Croce L and Benitah
SA: Targeting metastasis-initiating cells through the fatty acid
receptor CD36. Nature. 541:41–45. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Hunt EG, Hurst KE, Riesenberg BP, Kennedy
AS, Gandy EJ, Andrews AM, Del Mar Alicea Pauneto C, Ball LE,
Wallace ED, Gao P, et al: Acetyl-CoA carboxylase obstructs
CD8+ T cell lipid utilization in the tumor
microenvironment. Cell Metab. 36:969–983.e10. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
O'Sullivan D, van der Windt GJ, Huang SC,
Curtis JD, Chang CH, Buck MD, Qiu J, Smith AM, Lam WY, DiPlato LM,
et al: Memory CD8(+) T cells use cell-intrinsic lipolysis to
support the metabolic programming necessary for development.
Immunity. 41:75–88. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Hong M, Clubb JD and Chen YY: Engineering
CAR-T cells for next-generation cancer therapy. Cancer Cell.
38:473–488. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Timpanaro A, Piccand C, Dzhumashev D,
Anton-Joseph S, Robbi A, Moser J, Rössler J and Bernasconi M:
CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4
promote rhabdomyosarcoma clearance in orthotopic mouse models. J
Exp Clin Cancer Res. 42:2932023. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Sanomachi T, Katsuya Y, Nakatsura T and
Koyama T: Next-generation CAR-T and TCR-T cell therapies for solid
tumors: Innovations, challenges, and global development trends.
Cancers (Basel). 17:19452025. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Choi BK, Lee DY, Lee DG, Kim YH, Kim SH,
Oh HS, Han C and Kwon BS: 4-1BB signaling activates glucose and
fatty acid metabolism to enhance CD8+ T cell proliferation. Cell
Mol Immunol. 14:748–757. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
De Martino M, Rathmell JC, Galluzzi L and
Vanpouille-Box C: Cancer cell metabolism and antitumour immunity.
Nat Rev Immunol. 24:654–669. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Carr EL, Kelman A, Wu GS, Gopaul R,
Senkevitch E, Aghvanyan A, Turay AM and Frauwirth KA: Glutamine
uptake and metabolism are coordinately regulated by ERK/MAPK during
T lymphocyte activation. J Immunol. 185:1037–1044. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ruan T and Keshari KR: Imaging tumor
metabolism. Cold Spring Harb Perspect Med. 15:a0415512025.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Xu L, Huang G, Wang Y, Huang G, Liu J and
Chen R: 2-[18F]FDG PET-based quantification of lymph
node metabolic heterogeneity for predicting lymph node metastasis
in patients with colorectal cancer. Eur J Nucl Med Mol Imaging.
51:1729–1740. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Shi Y, Kotchetkov IS, Dobrin A, Hanina SA,
Rajasekhar VK, Healey JH and Sadelain M: GLUT1 overexpression
enhances CAR T cell metabolic fitness and anti-tumor efficacy. Mol
Ther. 32:2393–2405. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Giuffrida L, Sek K, Henderson MA, Lai J,
Chen AXY, Meyran D, Todd KL, Petley EV, Mardiana S, Mølck C, et al:
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor
enhances CAR T cell efficacy. Nat Commun. 12:32362021. View Article : Google Scholar : PubMed/NCBI
|
